A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.

ABSTRACT: Although the majority of papillary thyroid cancer (PTC) is indolent, a subset of PTC behaves aggressively despite the best available treatment. A major clinical challenge is to reliably distinguish early on between those patients who need aggressive treatment from those who do not. Using a large cohort of PTC samples obtained from The Cancer Genome Atlas (TCGA), we analyzed the association between disease progression and multiple forms of genomic data, such as transcriptome, somatic mutations, and somatic copy number alterations, and found that genes related to FOXM1 signaling pathway were significantly associated with PTC progression. Integrative genomic modeling was performed, controlling for demographic and clinical characteristics, which included patient age, gender, TNM stages, histol

SUBMITTER: Cheng Q 

PROVIDER: S-EPMC5369994 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature